RPG Life Sciences Carves Out API Business, Secures ₹243 Crore PE Backing to Build Integrated Pharma Platform
核心洞察
RPG Life Sciences completed a slump sale of its API business to wholly owned subsidiary RPG Active Pharma Limited (搜索) for ₹33.55 crore, effective August 15, 2026.
Healthcare private equity firm InvAscent (搜索) will invest up to ₹243 crore initially, with an aggregate commitment of up to ₹700 crore in tranches to fund organic and inorganic growth.
RPG Active Pharma is acquiring Raghava Life Sciences (搜索)' API business for up to ₹135 crore, adding 22 commercialized APIs and 7 development-stage assets.
RPG Life Sciences has executed a Business Transfer Agreement to slump sale its Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary, RPG Active Pharma Limited (搜索) (RPGAP), for ₹33.55 crore. The transaction, approved by the Board on July 29, 2026, and completed on August 15, 2026, aims to create a focused API entity with dedicated capital while the parent company concentrates on its formulations business.
The sale consideration of ₹33.55 crore is subject to adjustments based on actual assets and liabilities at closing, expected by September 30, 2026. Concurrently, RPGAP entered into an investment agreement with InvAscent (搜索), a healthcare-focused private equity firm. Funds managed by InvAscent will make an initial investment of up to ₹243 crore in RPGAP, with the parties committing to infuse an aggregate amount of up to ₹700 crore in tranches to fund organic and inorganic growth, including manufacturing expansion and product portfolio enhancement.
Financial Impact and Strategic Rationale
The API business contributed ₹95.06 crore to revenue in FY26, representing 13.54% of consolidated turnover. Its net worth stood at ₹70.92 crore as of March 31, 2026. Management stated that the spin-off allows sharper focus on API growth within the subsidiary structure.
Ashok Nair, Managing Director of RPG Life Sciences, noted that the partnership with InvAscent (搜索) brings 20 years of pharma investing experience to complement the company's execution track record. Dr. Jeevak Gupta, Managing Director of InvAscent, stated that the investment supports building a differentiated API business with long-term growth potential.
The restructuring highlights a divergence between the internal transfer price and market valuation. While the slump sale consideration was ₹33.55 crore against a net worth of ₹70.92 crore, the initial ₹243 crore investment by InvAscent (搜索) implies a significantly higher valuation for the subsidiary. This structure leverages the spin-off to attract specialized capital for expansion.
Acquisition Strategy and Portfolio Expansion
RPGAP has executed a Share Purchase Agreement to acquire 100% of Actis Generics Private Limited (搜索) (Actis), an API manufacturer based in Visakhapatnam. The acquisition cost is ₹80 crore, subject to working capital adjustments, with completion targeted by November 15, 2026. Actis reported a turnover of ₹48.24 crore in FY25.
Additionally, RPG Active Pharma is acquiring the API and intermediates business of Raghava Life Sciences (搜索) for up to ₹135 crore. The Raghava transaction brings a portfolio of 22 commercialized APIs and 7 development-stage assets, lowering time-to-market in chronic therapeutic segments. Raghava Life Sciences' API business reported approximately ₹19 crore in revenue for FY26.
RPG Life Sciences is actively scouting for strategic acquisitions over the next 12 months to expand its API portfolio and scale operations. The company is transforming its business model by scaling its synthetic API platform as a third growth engine alongside formulations.
Financial Performance Context
RPG Life Sciences reported a 15.8% year-on-year increase in consolidated revenue from operations to ₹195.7 crore for the quarter ended June 30, 2026 (Q1FY27). Consolidated profit after tax (PAT) rose 17.0% to ₹30.8 crore from ₹26.3 crore in the prior year period, while EBITDA expanded 17.9% to ₹48.0 crore with margins improving to 24.5% from 24.1%.
The API business delivered a strong 35.6% growth to ₹26.6 crore as units returned to operations following a fire incident in one of the manufacturing blocks during the prior year. The Domestic Formulations (DF) business contributed 68.3% of total sales and grew 14.8% to ₹132.5 crore, outperforming the broader Indian Pharma Market growth of 11.6%.
Regulatory Disclosures and Advisors
The disclosures were made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026. The transaction falls outside the Scheme of Arrangement and does not constitute the sale of substantially the whole undertaking under Section 180 of the Companies Act, 2013.
Khaitan & Co. acted as legal counsel, o3 Capital as financial advisor, Quillon Partners as legal counsel for the acquisition, and Deloitte undertook financial due diligence.
Market Implications
The move highlights a broader sector-shift in the Indian pharma space toward de-risking supply chains and adopting integrated API-to-formulation models. Success in scaling these acquired API assets could significantly improve RPG Life Sciences' gross margins and backward integration, enhancing its competitiveness in international formulations.
The Indian API sector is experiencing strong tailwinds as companies focus on local manufacturing and export opportunities. Strategic buyouts of established, compliant plants allow mid-sized pharma companies to bypass lengthy greenfield setup times and complex regulatory approvals, providing immediate market-ready capacity.
Key risks include potential delays in aligning operations and upgrading newly acquired manufacturing facilities to meet global regulatory standards, and the possibility that acquiring relatively low-revenue assets at a premium could depress return ratios in the short term if capacity utilization is not scaled rapidly.